

# Jamie John Kirkham

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8416389/publications.pdf>

Version: 2024-02-01

120  
papers

27,211  
citations

94269

37  
h-index

22102

113  
g-index

130  
all docs

130  
docs citations

130  
times ranked

30496  
citing authors

#	ARTICLE	IF	CITATIONS
1	RoB 2: a revised tool for assessing risk of bias in randomised trials. <i>BMJ: British Medical Journal</i> , 2019, 366, i4898.	2.4	10,984
2	ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. <i>BMJ, The</i> , 2016, 355, i4919.	3.0	8,654
3	The COMET Handbook: version 1.0. <i>Trials</i> , 2017, 18, 280.	0.7	1,128
4	The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. <i>BMJ: British Medical Journal</i> , 2010, 340, c365-c365.	2.4	896
5	Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias – An Updated Review. <i>PLoS ONE</i> , 2013, 8, e66844.	1.1	783
6	Core Outcome Set-STAndards for Development: The COS-STAD recommendations. <i>PLoS Medicine</i> , 2017, 14, e1002447.	3.9	427
7	Core Outcome Set-STAndards for Reporting: The COS-STAR Statement. <i>PLoS Medicine</i> , 2016, 13, e1002148.	3.9	404
8	Adverse Drug Reactions in Children – A Systematic Review. <i>PLoS ONE</i> , 2012, 7, e24061.	1.1	207
9	Multivariate and network meta-analysis of multiple outcomes and multiple treatments: rationale, concepts, and examples. <i>BMJ: British Medical Journal</i> , 2017, 358, j3932.	2.4	165
10	Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. <i>BMJ, The</i> , 2014, 349, g6501-g6501.	3.0	158
11	Development and Inter-Rater Reliability of the Liverpool Adverse Drug Reaction Causality Assessment Tool. <i>PLoS ONE</i> , 2011, 6, e28096.	1.1	157
12	Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions. <i>The Cochrane Library</i> , 2015, 2015, MR000035.	1.5	152
13	Evidence for the Selective Reporting of Analyses and Discrepancies in Clinical Trials: A Systematic Review of Cohort Studies of Clinical Trials. <i>PLoS Medicine</i> , 2014, 11, e1001666.	3.9	151
14	Can a core outcome set improve the quality of systematic reviews? – a survey of the Co-ordinating Editors of Cochrane review groups. <i>Trials</i> , 2013, 14, 21.	0.7	145
15	Core Outcome Set-STANDARDISED Protocol Items: the COS-STAP Statement. <i>Trials</i> , 2019, 20, 116.	0.7	145
16	Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. <i>Trials</i> , 2013, 14, 324.	0.7	138
17	Bias Due to Changes in Specified Outcomes during the Systematic Review Process. <i>PLoS ONE</i> , 2010, 5, e9810.	1.1	127
18	A methodological approach for assessing the uptake of core outcome sets using ClinicalTrials.gov: findings from a review of randomised controlled trials of rheumatoid arthritis. <i>BMJ: British Medical Journal</i> , 2017, 357, j2262.	2.4	93

#	ARTICLE	IF	CITATIONS
19	The Importance of Integration of Stakeholder Views in Core Outcome Set Development: Otitis Media with Effusion in Children with Cleft Palate. PLoS ONE, 2015, 10, e0129514.	1.1	93
20	Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a paediatric hospital. BMC Medicine, 2013, 11, 238.	2.3	88
21	Scoping review on interventions to improve adherence to reporting guidelines in health research. BMJ Open, 2019, 9, e026589.	0.8	86
22	Outcome reporting bias in trials: a methodological approach for assessment and adjustment in systematic reviews. BMJ: British Medical Journal, 2018, 362, k3802.	2.4	83
23	Adverse drug reactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital. British Journal of Clinical Pharmacology, 2014, 77, 545-553.	1.1	82
24	A multivariate meta-analysis approach for reducing the impact of outcome reporting bias in systematic reviews. Statistics in Medicine, 2012, 31, 2179-2195.	0.8	77
25	Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children – a prospective observational cohort study of 6,601 admissions. BMC Medicine, 2013, 11, 237.	2.3	77
26	Core outcome sets for prevention and treatment of postpartum haemorrhage: an international Delphi consensus study. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 83-93.	1.1	70
27	Adverse Drug Reactions Causing Admission to a Paediatric Hospital. PLoS ONE, 2012, 7, e50127.	1.1	70
28	Reporting of harms data in RCTs: a systematic review of empirical assessments against the CONSORT harms extension. BMJ Open, 2013, 3, e003436.	0.8	66
29	A review of the handling of missing longitudinal outcome data in clinical trials. Trials, 2014, 15, 237.	0.7	64
30	COS-STAR: a reporting guideline for studies developing core outcome sets (protocol). Trials, 2015, 16, 373.	0.7	64
31	National Audit of Seizure management in Hospitals (NASH): results of the national audit of adult epilepsy in the UK. BMJ Open, 2015, 5, e007325-e007325.	0.8	62
32	Cross-sectional study of prescribing errors in patients admitted to nine hospitals across North West England. BMJ Open, 2013, 3, e002036.	0.8	55
33	Systematic examination of preprint platforms for use in the medical and biomedical sciences setting. BMJ Open, 2020, 10, e041849.	0.8	54
34	Dexamethasone and haemorrhage risk in paediatric tonsillectomy: a systematic review and meta-analysis. British Journal of Anaesthesia, 2014, 113, 23-42.	1.5	50
35	The management of Otitis Media with Effusion in children with cleft palate (mOMEnt): a feasibility study and economic evaluation. Health Technology Assessment, 2015, 19, 1-374.	1.3	50
36	Navigating the landscape of core outcome set development in dermatology. Journal of the American Academy of Dermatology, 2019, 81, 297-305.	0.6	46

#	ARTICLE	IF	CITATIONS
37	How well are the ASAS/OMERACT Core Outcome Sets for Ankylosing Spondylitis implemented in randomized clinical trials? A systematic literature review. <i>Clinical Rheumatology</i> , 2014, 33, 1313-1322.	1.0	41
38	Assessing the impact of a research funder's recommendation to consider core outcome sets. <i>PLoS ONE</i> , 2019, 14, e0222418.	1.1	41
39	A randomized trial comparing three Delphi feedback strategies found no evidence of a difference in a setting with high initial agreement. <i>Journal of Clinical Epidemiology</i> , 2018, 93, 1-8.	2.4	38
40	Selective reporting of outcomes in randomised controlled trials in systematic reviews of cystic fibrosis. <i>BMJ Open</i> , 2013, 3, e002709.	0.8	37
41	Assessing the relevance and uptake of core outcome sets (an agreed minimum collection of outcomes) Tj ETQq1 1 0,784314,rgBT /Over	0.8	37
42	Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 241-250.	0.5	36
43	Cross-sectional study of preprints and final journal publications from COVID-19 studies: discrepancies in results reporting and spin in interpretation. <i>BMJ Open</i> , 2021, 11, e051821.	0.8	35
44	A Core Outcome Set for the prevention and treatment of fetal GROWth restriction: deVeloPping Endpoints: the COSGROVE study. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 339.e1-339.e10.	0.7	33
45	Use of core outcome sets was low in clinical trials published in major medical journals. <i>Journal of Clinical Epidemiology</i> , 2022, 142, 19-28.	2.4	33
46	Core Outcome Set for Actinic Keratosis Clinical Trials. <i>JAMA Dermatology</i> , 2020, 156, 326.	2.0	31
47	A model-based correction for outcome reporting bias in meta-analysis. <i>Biostatistics</i> , 2014, 15, 370-383.	0.9	28
48	Development of the Liverpool Adverse Drug Reaction Avoidability Assessment Tool. <i>PLoS ONE</i> , 2017, 12, e0169393.	1.1	26
49	The transition of adolescents with juvenile idiopathic arthritis or epilepsy from paediatric health-care services to adult health-care services: A scoping review of the literature and a synthesis of the evidence. <i>Journal of Child Health Care</i> , 2018, 22, 332-358.	0.7	23
50	Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK Alert Level 4 phase of the B-MaP-C study. <i>British Journal of Cancer</i> , 2021, 124, 1785-1794.	2.9	21
51	Effect of an editorial intervention to improve the completeness of reporting of randomised trials: a randomised controlled trial. <i>BMJ Open</i> , 2020, 10, e036799.	0.8	20
52	Overview of systematic reviews of therapeutic ranges: methodologies and recommendations for practice. <i>BMC Medical Research Methodology</i> , 2017, 17, 84.	1.4	19
53	The patterning of hypodontia in a group of young adults in Sheffield, UK. <i>Archives of Oral Biology</i> , 2005, 50, 287-291.	0.8	18
54	Selective outcome reporting: telling and detecting true lies. The state of the science. <i>Internal and Emergency Medicine</i> , 2010, 5, 151-155.	1.0	18

#	ARTICLE	IF	CITATIONS
55	The Reporting of Harms in Randomized Controlled Trials of Hypertension Using the CONSORT Criteria for Harm Reporting. <i>Clinical and Experimental Hypertension</i> , 2012, 34, 548-554.	0.5	18
56	The effect of outdoor air pollution on the risk of hospitalisation for bronchiolitis in infants: a systematic review. <i>PeerJ</i> , 2018, 6, e5352.	0.9	18
57	Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use. <i>Trials</i> , 2015, 16, 268.	0.7	17
58	Development of interferon beta-neutralising antibodies in multiple sclerosis—a systematic review and meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1287-1298.	0.8	17
59	Citation analysis did not provide a reliable assessment of core outcome set uptake. <i>Journal of Clinical Epidemiology</i> , 2017, 86, 153-159.	2.4	17
60	Strengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guideline. <i>PLoS Medicine</i> , 2020, 17, e1003344.	3.9	17
61	ADRIC: Adverse Drug Reactions In Children — a programme of research using mixed methods. <i>Programme Grants for Applied Research</i> , 2014, 2, 1-184.	0.4	17
62	A comparison of hospital performance with non-ignorable missing covariates: An application to trauma care data. <i>Statistics in Medicine</i> , 2008, 27, 5725-5744.	0.8	16
63	Referral patterns after a seizure admission in an English region: an opportunity for effective intervention? An observational study of routine hospital data. <i>BMJ Open</i> , 2016, 6, e010100.	0.8	15
64	Management of medial humeral epicondyle fractures in children: a structured review protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. <i>Trials</i> , 2018, 19, 119.	0.7	15
65	Model-based sensitivity analysis for outcome reporting bias in the meta analysis of benefit and harm outcomes. <i>Statistical Methods in Medical Research</i> , 2019, 28, 889-903.	0.7	15
66	Multivariate meta-analysis helps examine the impact of outcome reporting bias in Cochrane rheumatoid arthritis reviews. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 542-550.	2.4	14
67	Systematic review: outcomes and adverse events from randomised trials in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 978-996.	1.9	14
68	Interventions to improve adherence to reporting guidelines in health research: a scoping review protocol. <i>BMJ Open</i> , 2017, 7, e017551.	0.8	13
69	Who and why do researchers opt to publish in post-publication peer review platforms? - findings from a review and survey of F1000 Research. <i>F1000Research</i> , 2018, 7, 920.	0.8	13
70	Assessing uptake of the Harmonising Outcome Measures for Eczema (HOME) Core Outcome Set and recommended instruments. <i>British Journal of Dermatology</i> , 2020, 183, 566-568.	1.4	13
71	The Use of Statistical Process Control for Monitoring Institutional Performance in Trauma Care. <i>Journal of Trauma</i> , 2008, 65, 1494-1501.	2.3	12
72	Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol). <i>Systematic Reviews</i> , 2017, 6, 142.	2.5	11

#	ARTICLE	IF	CITATIONS
73	Industry funding was associated with increased use of core outcome sets. <i>Journal of Clinical Epidemiology</i> , 2019, 115, 90-97.	2.4	11
74	Improvement was needed in the standards of development for cancer core outcome sets. <i>Journal of Clinical Epidemiology</i> , 2019, 112, 36-44.	2.4	11
75	A pilot randomised controlled trial to assess the utility of an e-learning package that trains users in adverse drug reaction causality. <i>International Journal of Pharmacy Practice</i> , 2015, 23, 447-455.	0.3	10
76	Feasibility study to examine discrepancy rates in prespecified and reported outcomes in articles submitted to <i>The BMJ</i> . <i>BMJ Open</i> , 2016, 6, e010075.	0.8	10
77	CYP genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2018, 7, 204.	2.5	10
78	Development of a core outcome set for amblyopia, strabismus and ocular motility disorders: a review to identify outcome measures. <i>BMC Ophthalmology</i> , 2019, 19, 47.	0.6	10
79	Empirical comparison of univariate and multivariate meta-analyses in Cochrane Pregnancy and Childbirth reviews with multiple binary outcomes. <i>Research Synthesis Methods</i> , 2019, 10, 440-451.	4.2	9
80	Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews. <i>Arthritis Research and Therapy</i> , 2020, 22, 177.	1.6	9
81	COHESION: core outcomes in neonatal encephalopathy (protocol). <i>Trials</i> , 2021, 22, 125.	0.7	9
82	Multi-Round compared to Real-Time Delphi for consensus in core outcome set (COS) development: a randomised trial. <i>Trials</i> , 2021, 22, 142.	0.7	9
83	How Much Participant Outcome Data Is Missing from Sight: Findings from a Cohort of Trials Submitted to a German Research Ethics Committee. <i>PLoS ONE</i> , 2016, 11, e0157883.	1.1	8
84	Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease. <i>Pharmacoeconomics</i> , 2019, 37, 1509-1523.	1.7	7
85	Development of core outcome sets for vision screening and assessment in stroke: a Delphi and consensus study. <i>BMJ Open</i> , 2019, 9, e029578.	0.8	7
86	Development of a core outcome set for cutaneous squamous cell carcinoma trials: identification of core domains and outcomes*. <i>British Journal of Dermatology</i> , 2021, 184, 1113-1122.	1.4	7
87	A survey exploring biomedical editors' perceptions of editorial interventions to improve adherence to reporting guidelines. <i>F1000Research</i> , 0, 8, 1682.	0.8	7
88	Postinflammatory hyperpigmentation: protocol for development of a core outcome set for clinical trials. <i>Archives of Dermatological Research</i> , 2022, 314, 357-361.	1.1	6
89	Development of processes allowing near real-time refinement and validation of triage tools during the early stage of an outbreak in readiness for surge: the FLU-CATs Study. <i>Health Technology Assessment</i> , 2015, 19, 1-132.	1.3	6
90	Development of a core outcome set for multimorbidity trials in low/middle-income countries (COSMOS): study protocol. <i>BMJ Open</i> , 2022, 12, e051810.	0.8	6

#	ARTICLE	IF	CITATIONS
91	Do systematic reviews still exclude studies with “no relevant outcome data”? BMJ: British Medical Journal, 2017, 358, j3919.	2.4	5
92	Outcome reporting bias in Cochrane systematic reviews: a cross-sectional analysis. BMJ Open, 2020, 10, e032497.	0.8	5
93	Development of a core outcome set for basal cell carcinoma. Journal of the American Academy of Dermatology, 2022, 87, 573-581.	0.6	5
94	Clinical coding of prospectively identified paediatric adverse drug reactions “ a retrospective review of patient records. BMC Pharmacology & Toxicology, 2014, 15, 72.	1.0	4
95	Splinting for the non-operative management of developmental dysplasia of the hip (DDH) in children under six months of age. The Cochrane Library, 2017, , .	1.5	4
96	Representation of published core outcome sets for research in regulatory guidance: protocol. HRB Open Research, 2021, 4, 45.	0.3	4
97	Protocol for development of a core outcome set for clinical trials in melasma. BMJ Open, 2022, 12, e046953.	0.8	4
98	Protocol for the development of the STrengthening the Reporting Of Pharmacogenetic Studies (STROPS) guideline: checklist of items for reporting pharmacogenetic studies. BMJ Open, 2019, 9, e030212.	0.8	3
99	Representation of published core outcome sets for research in regulatory guidance: protocol. HRB Open Research, 2021, 4, 45.	0.3	3
100	Representation of published core outcome sets for research in regulatory guidance: protocol. HRB Open Research, 0, 4, 45.	0.3	3
101	A survey exploring biomedical editors’™ perceptions of editorial interventions to improve adherence to reporting guidelines. F1000Research, 2019, 8, 1682.	0.8	3
102	Uptake of core outcome sets by clinical trialists publishing in major medical journals: Protocol. HRB Open Research, 2020, 3, 53.	0.3	3
103	Using behavioural science to enhance use of core outcome sets in trials: protocol. HRB Open Research, 0, 5, 23.	0.3	3
104	Selective reporting in clinical trials - an examination of discrepancy rates in pre-specified and reported outcomes in articles submitted to the BMJ. Trials, 2015, 16, .	0.7	2
105	Pain Measurement in Rheumatic and Musculoskeletal Diseases: Where To Go from Here? Report from a Special Interest Group at OMERACT 2018. Journal of Rheumatology, 2019, 46, 1355-1359.	1.0	2
106	Use of composite outcomes facilitate core outcome set uptake in rheumatoid arthritis trials. Annals of the Rheumatic Diseases, 2020, 79, 301-302.	0.5	2
107	Patient-focused outcomes are infrequently reported in pediatric health information technology trials: a systematic review. Journal of Clinical Epidemiology, 2020, 119, 117-125.	2.4	2
108	Core outcome set for three ophthalmic conditions: a healthcare professional and patient consensus on core outcome sets for amblyopia, ocular motility and strabismus (COSAMS Study). BMJ Open, 2021, 11, e042403.	0.8	2

#	ARTICLE	IF	CITATIONS
109	NATIONAL AUDIT OF SEIZURE MANAGEMENT IN HOSPITALS: INITIAL FINDINGS. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, A36.3-A36.	0.9	2
110	Improving peer review of systematic reviews by involving librarians and information specialists: protocol for a randomized controlled trial. Trials, 2021, 22, 791.	0.7	2
111	Secondary analysis of data from a core outcome set for burns demonstrated the need for involvement of lower income countries. Journal of Clinical Epidemiology, 2022, 144, 56-71.	2.4	2
112	Meeting the ongoing challenges of outcome selection in surgical oncology trials. British Journal of Surgery, 2022, 109, 563-565.	0.1	2
113	Citation analysis: a new approach to assess the uptake of core outcome sets. Trials, 2015, 16, .	0.7	1
114	Development of core outcome sets and core outcome measures for central visual impairment, visual field loss and ocular motility disorders due to stroke: a Delphi and consensus study. BMJ Open, 2022, 12, e056792.	0.8	1
115	PWE-007â€¦A systematic review of outcomes and adverse events for randomised controlled trials in crohnâ€™s disease. , 2018, , .		0
116	Reply. American Journal of Obstetrics and Gynecology, 2020, 222, 390-391.	0.7	0
117	Uptake of core outcome sets by clinical trialists publishing in major medical journals: Protocol. HRB Open Research, 2020, 3, 53.	0.3	0
118	The effect of ambient air pollution on the risk of hospitalisation with bronchiolitis in infants: A systematic review.. , 2018, , .		0
119	Stage 1 Registered Report. Interventions for improving the design and conduct of scientific research: A scoping review. NIHR Open Research, 0, 2, 4.	0.0	0
120	Interventions for improving the design and conduct of scientific research: A scoping review protocol. NIHR Open Research, 0, 2, 4.	0.0	0